These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30114262)

  • 1. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction.
    DuBrock HM; AbouEzzeddine OF; Redfield MM
    PLoS One; 2018; 13(8):e0201836. PubMed ID: 30114262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
    Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM
    J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
    Wang H; Anstrom K; Ilkayeva O; Muehlbauer MJ; Bain JR; McNulty S; Newgard CB; Kraus WE; Hernandez A; Felker GM; Redfield M; Shah SH
    JAMA Cardiol; 2017 Aug; 2(8):896-901. PubMed ID: 28492915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).
    AbouEzzeddine OF; Haines P; Stevens S; Nativi-Nicolau J; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    JACC Heart Fail; 2015 Mar; 3(3):245-52. PubMed ID: 25742762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study.
    Reddy YNV; Lewis GD; Shah SJ; Obokata M; Abou-Ezzedine OF; Fudim M; Sun JL; Chakraborty H; McNulty S; LeWinter MM; Mann DL; Stevenson LW; Redfield MM; Borlaug BA
    Mayo Clin Proc; 2019 Jul; 94(7):1199-1209. PubMed ID: 31272568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial.
    Gandhi PU; Gaggin HK; Redfield MM; Chen HH; Stevens SR; Anstrom KJ; Semigran MJ; Liu P; Januzzi JL
    JACC Heart Fail; 2016 Nov; 4(11):860-869. PubMed ID: 27744089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction.
    Koller L; Kleber M; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer T; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
    Eur J Heart Fail; 2014 Jul; 16(7):758-66. PubMed ID: 24806206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction.
    Sabbah MS; Fayyaz AU; de Denus S; Felker GM; Borlaug BA; Dasari S; Carter RE; Redfield MM
    Circ Heart Fail; 2020 Aug; 13(8):e006414. PubMed ID: 32809874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
    Patel RB; Mehta R; Redfield MM; Borlaug BA; Hernandez AF; Shah SJ; Dubin RF
    J Card Fail; 2020 Mar; 26(3):233-242. PubMed ID: 31931098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
    Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
    Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.